Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy | Zendy

Leo Wang | Zendy; Gopal Patel | Zendy; Zelma C. Chiesa Fuxench | Zendy; Suzanne McGettigan | Zendy; Lynn M. Schuchter | Zendy; Tara C. Mitchell | Zendy; Michael E. Ming | Zendy; Emily Y. Chu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy

Author(s) -

Leo Wang,

Gopal Patel,

Zelma C. Chiesa Fuxench,

Suzanne McGettigan,

Lynn M. Schuchter,

Tara C. Mitchell,

Michael E. Ming,

Emily Y. Chu

Publication year - 2018

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2018.1912

Subject(s) - medicine , nivolumab , pembrolizumab , ipilimumab , toxic epidermal necrolysis , drug eruption , dermatology , retrospective cohort study , erythema , skin biopsy , biopsy , erythema multiforme , adverse effect , cancer , drug , immunotherapy , pharmacology

An increasing number of cutaneous adverse reactions resulting from use of programmed cell death protein 1 (PD-1) inhibitors have been described, but with relatively little focus to date on the timing of these reactions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research